New Analogues of Mycophenolic Acid

Publisher: Bentham Science Publishers

E-ISSN: 1875-5607|17|9|734-745

ISSN: 1389-5575

Source: Mini Reviews in Medicinal Chemistry, Vol.17, Iss.9, 2017-05, pp. : 734-745

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Background: Mycophenolic acid (MPA) possesses antibacterial, antifungal, antiviral, immunosuppressiveand anticancer properties. It is a non-competitive and reversible inhibitor of dehydrogenaseinosine-5#039;-monophosphate (IMPDH). This compound belongs to the immunosuppressivedrugs used for the prevention of both acute and chronic transplant rejection. Until now, two derivativesof MPA have been used clinically: mycophenolate mofetil (MMF, CellCept) and mycophenolate sodium(MPS, Myfortic). They cause, similar to MPA, although at lower degree, the side effects such asvomiting, abdominal pain, diarrhea, nausea, gastrointestinal, urogenital tract, blood or nervous systemdisorders. These drawbacks and glucuronidation of MPA in vivo limit the use of these compounds aspharmaceuticals. Therefore, research is still going on for more effective analogs that are less toxic tothe organism and could improve the quality of life of patients.Conclusion: In this review article, the authors present the synthesis of novel derivatives of mycophenolicacid, together with their initial biological investigations.